JAK Inhibitors for Alopecia Areata: Who Qualifies, How Well They Work and What Happens When You Stop
Short answer: JAK inhibitors (baricitinib, ritlecitinib, deuruxolitinib) are prescription tablets for severe alopecia areata, usually defined as hair loss over at least half of the scalp. In phase 3 trials, depending on the drug and dose, roughly a quarter to two-fifths of patients had at least 80% of the scalp covered with hair again after 6–9 months. The effect lasts only while the medicine is taken: after stopping, hair loss returns in most people. They are a treatment option that needs regular blood tests and medical follow-up, not a miracle pill.
Claim: “Oral JAK inhibitors regrow hair in severe alopecia areata.”
Evidence level: Strong — large randomised, placebo-controlled phase 3 trials and regulatory approvals; the effect lasts as long as treatment continues.
My recommendation: Only for severe or extensive disease, with screening tests and regular monitoring; not a first choice for limited patches.
I cover the overall picture — causes, how limited patches behave and steroid injections — in my alopecia areata article. This article focuses only on oral JAK inhibitors for extensive, persistent disease: who is a candidate, what the trials actually show, what happens when treatment stops and which tests are needed — and, because many readers ask, how to recognise that hair is growing back. How the scalp is examined is explained in trichoscopy and hair analysis.
How do JAK inhibitors work in alopecia areata?
In alopecia areata, immune cells attack hair follicles in their growth phase. Much of the signalling that keeps this attack going runs through the JAK–STAT pathway inside cells. JAK inhibitors dampen this pathway and calm the inflammation around the follicle. Because the follicle is not destroyed, hair can grow back once the attack stops. The same mechanism explains the limit: the medicine suppresses disease activity; it does not erase the disease.
Who is a candidate?
The current British Association of Dermatologists guideline gives a strong recommendation to offer a licensed oral JAK inhibitor to adults and to young people aged 13–17 with severe alopecia areata. Severe usually means that 50% or more of the scalp is affected (a SALT score of 50 or higher); alopecia totalis (whole scalp) and alopecia universalis (all body hair) belong to this group.
Adults: the baricitinib, ritlecitinib and deuruxolitinib trials enrolled adults with SALT ≥50.
Adolescents: ritlecitinib is approved in the European Union for severe alopecia areata from age 12; the other two are approved for adults.
Duration: after many years of complete hair loss, the chance of response is lower than in more recent disease, and this is part of the decision.
Availability and reimbursement differ between countries and can change; suitability is assessed at the consultation.
What do the trials show?
All three medicines have placebo-controlled phase 3 trials. Success was usually defined as SALT ≤20, meaning at least 80% of the scalp covered with hair:
Baricitinib (BRAVE-AA1 and BRAVE-AA2): at week 36, about 36–39% of patients on the higher dose and 19–23% on the lower dose reached SALT ≤20, versus 3–6% on placebo.
Ritlecitinib (ALLEGRO-2b/3, age 12 and over): at week 24, about 23% on the approved dose reached this target, versus only a few patients on placebo.
Deuruxolitinib (THRIVE-AA1 and THRIVE-AA2): at week 24, about 30–42% reached SALT ≤20 depending on the dose, versus under 1% on placebo.
Reading these numbers correctly matters: roughly one patient in three regains most of their hair, some respond partially and some show no meaningful change. Response is slow; the first new hairs usually appear after a few months, and in longer follow-up response rates kept rising beyond the first six months. There are no head-to-head trials, so the question of which one is strongest has no firm answer today.
Signs that alopecia areata is growing back
Whatever the treatment, regrowth tends to follow a recognisable pattern:
Fine, soft, short hairs appear inside the bald patch, a little like peach fuzz.
The first hairs are often white or colourless. Colour usually returns gradually over the following months.
The patch stops spreading. Short "exclamation mark" hairs at the edge become fewer, and hairs at the margin no longer come out easily with a gentle tug.
The new hairs thicken and darken over time; eyebrows and eyelashes may follow at a different pace from the scalp.
On trichoscopy, short upright regrowing hairs replace the black dots and broken hairs of active disease.
White regrowth is a good sign, not a new problem. A new patch appearing elsewhere while another one regrows is also common and does not mean that treatment has failed.
What happens when you stop?
This is the question that needs the most honest answer. In the baricitinib withdrawal study, some patients who had responded well after a year of treatment were switched to placebo. Of those who stopped, 80% lost their benefit over the next two years, mostly 2–6 months after stopping. About 90% of those who continued kept their response. When the medicine was restarted, most patients regained their response.
In severe alopecia areata, a JAK inhibitor is therefore not a cure but maintenance treatment that keeps the disease suppressed. Decisions about lowering the dose or pausing are made only with medical follow-up, based on how the disease behaves.
Safety: what are the risks and which tests are needed?
JAK inhibitors act on the immune system. Regulators in Europe, the UK and the US have issued warnings for this drug class about serious infections, venous thrombosis (blood clots), major cardiovascular events and cancer; extra caution applies to people over 65, smokers and those with cardiovascular risk factors. In the alopecia areata trials, the most common side effects were upper respiratory infections, headache, acne and raised blood lipids.
Before starting
Full blood count, liver and kidney tests, blood lipids
Tuberculosis screening; hepatitis B, hepatitis C and, where appropriate, HIV tests
Pregnancy test and effective contraception during treatment; these medicines are not used in pregnancy or breastfeeding
Review of vaccinations (especially shingles) and of any past blood clots; no live vaccines during treatment
During treatment
Blood count and liver tests are checked more often in the first months and then at set intervals; lipids are rechecked a few months after starting. Fever, an infection that does not settle, a shingles rash, one-sided leg swelling and pain, or sudden breathlessness need prompt medical attention. Dose and monitoring intervals are set by the doctor for each person; these are not medicines to start on your own or to take on someone else's prescription.
Who is not a candidate?
People with an active serious infection, untreated tuberculosis or active hepatitis
Women who are pregnant, planning a pregnancy or breastfeeding
People with a past deep vein thrombosis or pulmonary embolism, or high cardiovascular risk (only after careful individual assessment)
People on active cancer treatment, with severe liver impairment or markedly low blood counts
Hair loss that is not actually alopecia areata: ringworm, trichotillomania (hair pulling) and scarring alopecia must be ruled out before systemic treatment
Why not first choice for limited patches?
When alopecia areata is limited to one or a few patches, hair grows back within a year in a large share of patients, with or without simple treatment. Guidelines recommend steroid injections into the patch for adults and potent topical steroids for children as first-line options. Adding the risks of a systemic immune medicine to a condition with a good chance of settling on its own is not the right balance — and JAK inhibitors are not approved for limited disease. If patches spread quickly, exceed half of the scalp or turn into a stubborn pattern such as ophiasis, the plan is reassessed.
Eyebrows, eyelashes and nails
Loss of eyebrows and eyelashes is among the features that affect quality of life most. In the phase 3 trials, eyebrows and eyelashes also regrew in many patients, often together with the scalp and sometimes a little later. Data on nail involvement (pitting, roughness) are more limited, although improvement has been reported in some patients. During follow-up, response is documented with photographs of the eyebrows, lashes and nails as well as the scalp.
Children and teenagers
Ritlecitinib is approved in the European Union for patients aged 12 and over with severe alopecia areata. No JAK inhibitor is approved for alopecia areata under 12; at that age treatment is usually topical. For teenagers, the decision is made together with the family, considering the extent, the duration and the effect on school and social life. The psychological burden of hair loss is part of the plan, and child and adolescent mental health support is added when needed.
When to see a dermatologist
Patches are growing or merging over a few months
More than half of the scalp, the eyebrows or the eyelashes are affected
Patches have not closed after a year despite injections or topical treatment
Fever, infection, leg swelling or breathlessness while taking a JAK inhibitor
Treatment with a JAK inhibitor means regular check-ups and blood tests. For patients travelling to my practice in Kırklareli, we plan together at the first visit how follow-up will be organised.
Frequently asked questions
What are the signs of regrowth in alopecia areata?
Fine, soft, short hairs appear in the patch, often white or colourless at first; the patch stops spreading, and the hairs gradually thicken and regain their colour over the following months.
Are there natural remedies for alopecia areata that work?
No home remedy has proven benefit, and garlic, onion juice or chilli preparations can irritate the scalp. Evidence-based options are steroid injections and topical steroids for limited patches, and JAK inhibitors or contact immunotherapy for extensive disease.
Do JAK inhibitors cure alopecia areata?
No. They suppress the disease; after stopping, hair loss returns within months in most patients, so treatment is a long-term decision.
How long do JAK inhibitors take to work?
The first new hairs usually appear within a few months. Trials assessed response at weeks 24–36, and response could continue to improve after that.
Which blood tests are needed on a JAK inhibitor?
Before starting: blood count, liver and kidney tests, lipids, and screening for tuberculosis and hepatitis. During treatment, blood count, liver tests and lipids are rechecked at set intervals.
Can teenagers take a JAK inhibitor for alopecia areata?
Ritlecitinib is approved in the European Union for severe alopecia areata from age 12. No JAK inhibitor is approved under 12, and the decision is always made with a dermatologist.
References
King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687-1699. DOI
King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet. 2023;401(10387):1518-1529. DOI
King B, Senna MM, Mesinkovska NA, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024;91(5):880-888. DOI
King B, Ko J, Kwon O, et al. Baricitinib withdrawal and retreatment in patients with severe alopecia areata: the BRAVE-AA1 randomized clinical trial. JAMA Dermatol. 2024;160(10):1075. DOI
Harries MJ, Ascott A, Asfour L, et al. British Association of Dermatologists living guideline for managing people with alopecia areata 2024. Br J Dermatol. 2025;192(2):190-205. DOI
This article is for general information; diagnosis and treatment are decided after examination.
Last updated: 24 October 2026 · Dr. Kağan Cingöz, MD, dermatologist
Contact
WhatsApp / Viber: +90 555 209 09 39 · info@drkagancingoz.com · İstasyon Mahallesi, Edirne Caddesi No:102, Kırklareli, Türkiye
Comments